AKR1C1 and urinary bladder carcinoma: The effect and mechanism of AKR1C1 on THP resistance in bladder cancer were explored using cell biology, molecular biology, and pharmacology and combined with AKR1C1 inhibitor (aspirin) and ROS inhibitor (scavenger) to rescue drug-resistant bladder cancer cells to recover their sensitivity to THP.